• Nenhum resultado encontrado

Arq Bras Endocrinol Metab vol.51 número5

N/A
N/A
Protected

Academic year: 2018

Share "Arq Bras Endocrinol Metab vol.51 número5"

Copied!
2
0
0

Texto

(1)

641 Arq Bras Endocrinol Metab 2007;51/5

O

VER THE PAST DECADEwe have witnessed important advances in our understanding of the pathogenesis of thyroid cancer, and in the approaches we use to diagnose and manage patients with the disease. Many of these have been the product of technological developments, which have given rise to both new opportunities and challenges. Take, for instance, the widespread use of cross-sectional imaging and the introduction of neck ultrasonography, which have improved the sensitivity for detection of thy-roid cancer that is now often found incidentally as a result of imaging stud-ies done for other indications. Consequently, this has led to the identifica-tion of many patients with microscopic papillary thyroid cancers of uncer-tain clinical significance. There are also new approaches for surveillance of patients with an established diagnosis of thyroid cancer, and their refine-ment is leading to the observation that many patients, previously thought to be cured, have evidence of minimal residual disease. Physicians taking care of patients with this disease now have to grapple with a new array of issues that directly affect decisions they make in their daily practice. This special issue of ABE&M on thyroid cancer is therefore particularly timely. Many of the most prominent Brazilian and international investigators and thought leaders working in this field provide updates on a wide spectrum of topics, including epidemiology, genetics, pathogenesis as well as surgi-cal and clinisurgi-cal management of thyroid cancer. Breakthroughs arising from better understanding of the molecular genetics of thyroid cancer are now becoming relevant to the management of the disease, and it is increasing-ly important that clinicians understand them. This issue covers the most important aspects of thyroid cancer genetics, and how this applies to diag-nosis, prognosis and treatment of patients with refractory disease. Indeed, development of targeted therapies results directly from the identification of the key oncogenic mutations that drive growth of thyroid cancer, and these will be reaching clinical practice in the very near future. Finally, the increasing complexity of issues affecting the management of patients with thyroid nodular disease and thyroid cancer requires that thought leaders reach consensus on guidelines for care. Also in this issue, a group of rec-ognized Brazilian experts provide a comprehensive set of recommenda-tions for care based on the evidence in the literature.

Câncer de Tiróide: Passado, Presente e Futuro

A

ÚLTIMA DÉCADA TROUXE importantes avanços no entendimento da patogênese do câncer da tiróide, assim como na conduta que uti-lizamos para o diagnóstico da doença e tratamento dos pacientes. Muitos desses avanços decorrem do progresso tecnológico que tem proporcionado novas oportunidades, e também novos desafios. Assim, por exemplo, o amplo uso da ultra-sonografia cervical aumentou a sensibilidade na detecção do câncer da tiróide, que vem sendo freqüentemente encontrado por acaso, como resultado de estudos de imagem realizados por outras

editorial

Thyroid Cancer: Past, Present and Future

JAMESA. FAGIN

LAURAS. WARD

EDNAT. KIMURA

(2)

indicações. Conseqüentemente, têm-se identificado muitos pacientes com carcinomas papilíferos micros-cópicos, cujo significado clínico ainda é incerto. Além disso, novas condutas de acompanhamento de pacientes com diagnóstico confirmado de câncer de tiróide, e o refi-namento desses métodos de seguimento, vêm levando à observação de que muitos pacientes anteriormente considerados curados têm evidência de doença residual mínima. O profissional vem sendo confrontado com uma gama de novas questões que afetam diretamente suas decisões diárias na prática clínica. Esta edição especial dos ABE&M em câncer da tiróide é, portanto, bastante apropriada nas circunstâncias que vivenciamos. Vários dos mais proeminentes pesquisadores brasileiros e interna-cionais, líderes em seus campos de pesquisa, colaboram com atualizações em amplo espectro de tópicos, que in-cluem epidemiologia, genética e patogênese, assim como a conduta clínica e cirúrgica no câncer da tiróide. Avanços advindos da melhor compreensão da genética molecular

do câncer da tiróide vêm se tornando agora relevantes para o manejo da doença, e é importante que os clíni-cos compreendam estes conceitos. Esta edição cobre os mais importantes aspectos na genética do câncer da tiróide, e como este conhecimento pode ser aplicado no diagnóstico, prognóstico e tratamento de pacientes com doença refratária. Na verdade, o desenvolvimento de terapias específicas resulta da identificação de mu-tações oncogênicas chaves, responsáveis pela progres-são do câncer de tiróide, e isto deve chegar à prática clínica num futuro bem próximo. Finalmente, a cres-cente complexidade das questões que afetam a con-duta de pacientes com doença nodular e com câncer da tiróide, requer que especialistas neste assunto alcan-cem um consenso nas diretrizes de tratamento. Além disso, nesta edição, um grupo de reconhecidos espe-cialistas brasileiros oferece uma ampla série de reco-mendações para tratamento baseada nas mais recentes evidências da literatura.

Thyroid Cancer

Fagin, Ward & Kimura

Referências

Documentos relacionados

After genetic testing and identification of a germline mutation (c496G>T; V166F), II-4 and III-1 were identified as asymptomatic carriers.. Initially lost to follow-up, II-4 came

There are also new approaches for surveillance of patients with an established diagnosis of thyroid cancer, and their refine- ment is leading to the observation that many

Within thyroid neoplasias, BRAF mutations (V600E) were frequently detected in sporadic PTC (29–83%) (47-50), ranking as the major genetic alter- ation of this type of human

In fact, cAMP inhibits growth in some human thyroid tumoral cell lines (82,83) perhaps involving negative feed back mechanisms such as over expression of PDE4, as described

Histone deacetylase Treatment of thyroid cancer cell lines with histone deacetylase inhibitors inhibitors increases NIS expression as well as iodide uptake Pax8 expression

In general, chron- ic iodine deficiency and residence in an endemic goiter area are associated with an increased risk of follicular histological type of cancer, whereas chronically

In addition, we were not able to find any correlation between smoking, clinical features, parameters of aggressiveness at diagnosis or during fol- low-up of 248 patients with

The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has given a final answer to several questions. In fact, it has been demonstrated